Intellikine: Build-to-Sell in Biotech

by Larry Lasky


The Intellikine case study provides an example of a biotech company where its management team, founders, and investors sold the company at a relatively early stage of the company's development. In early 2012, Troy Wilson, the CEO of Intellikine sold the company to Millennium - The Takeda Oncology Company, Takeda's business unit responsible for global oncology, strategy, and development. The deal was for as much as $310 million (Millennium would pay $190 million upfront, with an additional $120 million dependent on clinical development milestones). By 2011, the Intellikine team had advanced three programs into human clinical testing. The key question for students is whether Wilson and his team sold the company too early or not. Various perspectives and the company strategy and execution are provided in the case study to allow students to have a fruitful discussion on each side of the argument.


Details

Pub Date: Jan 31, 2013

Discipline: Entrepreneurship

Subjects: Health care, Startup, Mergers & acquisitions, Entrepreneurship, Innovation, Leadership, Corporate strategy, Start-ups

Product #: B5763-PDF-ENG

Industry: Biotechnology,Pharmaceuticals

Geography: United States, California

Length: 11 page(s)

California Management Review

Berkeley-Haas's Premier Management Journal

Published at Berkeley Haas for more than sixty years, California Management Review seeks to share knowledge that challenges convention and shows a better way of doing business.

Learn more
Follow Us